The EDEM3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from human A-549 cells, with targeted disruption of the EDEM3 gene. This heterogeneous cell pool enables functional loss-of-function studies without clonal selection, providing a practical model for investigating ER-associated degradation (ERAD) and glycoprotein quality control in a lung epithelial context.
The A-549 cell line, established from a human lung adenocarcinoma, is widely employed as a model of alveolar type II epithelial cells. These cells retain key features of pulmonary epithelium, including surfactant production and barrier properties, making them suitable for studies of lung cancer biology, epithelial stress responses, and drug metabolism. Their amenability to genetic manipulation and standardized culture conditions facilitates reproducible knockout cell generation and downstream assays.
EDEM3 encodes an ER-resident mannosidase homolog that trims mannose residues from N-linked glycans on misfolded glycoproteins, a critical step in generating ERAD signals. Its expression is upregulated by the UPR transcription factors XBP1, ATF6, and ATF4 in response to ER stress inducers such as tunicamycin. EDEM3 physically and functionally interacts with the SEL1L?CHRD1 E3 ligase complex, the lectin OS9, and the chaperone calnexin to facilitate substrate recognition and retrotranslocation via VCP/p97 for proteasomal degradation. Disruption of EDEM3 ablates this mannose-trimming function, causing misfolded glycoprotein accumulation, chronic UPR activation, and sensitization to apoptosis.
In the A-549 cellular context, EDEM3 knockout provides a relevant model to investigate ER stress-driven pathology in lung adenocarcinoma. Alveolar epithelial cells are subject to high secretory demands and environmental stressors; loss of EDEM3-mediated ERAD exacerbates protein-folding stress, potentially revealing vulnerabilities of tumor cells that rely on robust quality-control mechanisms. This model enables dissection of the interplay between glycoprotein misfolding, UPR signaling outcomes, and cell-fate decisions, with implications for congenital disorders of glycosylation and ER stress-associated diseases.
Researchers can utilize this polyclonal knockout population for comprehensive ER stress analysis by Western blotting for EDEM3 and UPR markers such as BiP and CHOP, RT-qPCR for XBP1 splicing and UPR target genes, and immunofluorescence microscopy to visualize misfolded protein aggregates. Functional readouts include flow cytometry-based apoptosis assays, cell viability measurements under pharmacological ER stress, and transcriptomic profiling via RNA-seq. These cells are well-suited for drug screening campaigns seeking ERAD modulators or UPR-targeted therapeutics. For additional information, customized gene-editing services, or order inquiries, please contact Ascent Research.
